Purpose
To investigate the in vitro susceptibility of
Gram-positive and Gram-negative endophthalmitis bacterial isolates to
vancomycin, amikacin, and ceftazidime over a 23-year period.
Design
Retrospective non-comparative laboratory case series.
Subjects
Endophthalmitis patients that were culture positive for bacteria.
Methods
Laboratory records of bacteria isolated from endophthalmitis
specimens collected from January 1st 1993 to December
31st 2015 were reviewed for incidence and standard
susceptibility testing.
Main outcome measures
The in vitro susceptibilities of bacteria cultured
from endophthalmitis to vancomycin (VAN), amikacin (AMK), and ceftazidime
(CEF).
Results
Patients with endophthalmitis were culture positive for bacteria in
665 cases.. Coagulase negative Staphylococci (CoNS) were
the most common bacteria (54.6%), followed by
Streptococci (Strep) species (20.8%),
Staphylococcus aureus (SA) (10.2%), other
Gram-positive (other-GP) bacteria (7.4%) and Gram-negative (GN)
bacteria (7.1%). All Gram-positive organisms were susceptible to
VAN, with the exception of 2 isolates. The in vitro
susceptibilities of bacteria to AMK were: CoNS (95.3%), SA
(75.0%), Strep (8.0%), GN (95.7%), and other-GP
(81.1%). The in vitro susceptibilities of bacteria
to CEF were: CoNS (58.5%), SA (54.4%), Strep
(84.1%), GN (93.6.%), and other-GP (52.8%). There
was no difference between AMK (95.7%) and CEF (93.6%) for GN
coverage. AMK provided better coverage than CEF for CoNS, SA, and other-GP
bacteria respectively (p<0.05, Fisher's exact), however, CEF
appeared to provide better coverage (p<0.001, Fisher's
exact) for Strep than AMK.
Conclusions
Based on standard in vitro susceptibility testing,
vancomycin remains an optimal antibiotic choice for the treatment of
Gram-positive endophthalmitis. AMK and CEF appear to provide equal GN
coverage, but AMK appears to provide better coverage for CoNS, SA, and
other-GP, but not Strep.